Enliven Therapeutics (ELVN) Depreciation & Amortization (CF) (2019 - 2026)
Enliven Therapeutics has reported Depreciation & Amortization (CF) over the past 8 years, most recently at $14000.0 for Q1 2026.
- Quarterly results put Depreciation & Amortization (CF) at $14000.0 for Q1 2026, down 81.08% from a year ago — trailing twelve months through Mar 2026 was $240000.0 (down 18.92% YoY), and the annual figure for FY2025 was $300000.0, changed 0.0%.
- Depreciation & Amortization (CF) reached $14000.0 in Q1 2026 per ELVN's latest filing, down from $83000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $39.0 million in Q1 2022 and bottomed at $14000.0 in Q1 2026.
- Median Depreciation & Amortization (CF) over the past 5 years was $74000.0 (2023), compared with a mean of $2.4 million.
- The largest annual shift saw Depreciation & Amortization (CF) soared 155900.0% in 2022 before it crashed 99.83% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $49000.0 in 2022, then soared by 63.27% to $80000.0 in 2023, then fell by 21.25% to $63000.0 in 2024, then soared by 31.75% to $83000.0 in 2025, then crashed by 83.13% to $14000.0 in 2026.
- Business Quant data shows Depreciation & Amortization (CF) for ELVN at $14000.0 in Q1 2026, $83000.0 in Q4 2025, and $62000.0 in Q3 2025.